102 related articles for article (PubMed ID: 27080631)
1. [Not Available].
Pavlovic M; Garnier J; Durand-Zaleski I;
Therapie; 2016 Feb; 71(1):59-67. PubMed ID: 27080631
[No Abstract] [Full Text] [Related]
2. Progression-free survival, overall survival and quality of life: What is their medicoeconomic importance in oncology?
Pavlovic M; Garnier J; Durand-Zaleski I; ; Bilbault P; Gaudin AF; Le Jeunne C; Lalaude O; Roze S; de Sahb R; Sapède C
Therapie; 2016 Dec; 71(6):625-632. PubMed ID: 27639631
[TBL] [Abstract][Full Text] [Related]
3. Can we afford the war on cancer?
Szucs TD
Onkologie; 2008 Mar; 31(3):81. PubMed ID: 18322408
[No Abstract] [Full Text] [Related]
4. Statistics in oncology.
Land SR; Abrams J; Buyse M; Chappell RJ
J Clin Oncol; 2008 Aug; 26(22):3668. PubMed ID: 18669450
[No Abstract] [Full Text] [Related]
5. Oncological resource allocation in Germany.
Hartmann M; Kath R; Gundermann C
Onkologie; 2008 Mar; 31(3):85-9. PubMed ID: 18322410
[TBL] [Abstract][Full Text] [Related]
6. Value and payment for oncology in the United States.
Robinson JC
Ann Pharm Fr; 2013 Sep; 71(5):285-90. PubMed ID: 24075699
[TBL] [Abstract][Full Text] [Related]
7. Many new cancer drugs in the United Kingdom are facing negative NICE rulings.
Low E;
J Clin Oncol; 2007 Jun; 25(18):2635-6; author reply 2637-8. PubMed ID: 17577049
[No Abstract] [Full Text] [Related]
8. Value-based reimbursement in oncology.
Kolodziej M; Hoverman JR
Am J Manag Care; 2012 May; 18(3 Spec No.):SP124-6. PubMed ID: 22642278
[No Abstract] [Full Text] [Related]
9. [Equal access to patient education in oncology in France: Myth or reality?].
Huteau ME; Berger V; Hureau M; Boucher S; Stoebner-Delbarre A
Bull Cancer; 2019 Dec; 106(12):1196-1198. PubMed ID: 31604570
[No Abstract] [Full Text] [Related]
10. Reply to J.A. de Souza et al.
Khera N
J Clin Oncol; 2015 Apr; 33(12):1415-6. PubMed ID: 25732169
[No Abstract] [Full Text] [Related]
11. [Oncology caught between economics and efficiency].
Keil TU
Med Klin (Munich); 2000 Jun; 95 Suppl 1():1. PubMed ID: 10941245
[No Abstract] [Full Text] [Related]
12. Reporting and grading financial toxicity.
Khera N
J Clin Oncol; 2014 Oct; 32(29):3337-8. PubMed ID: 25199760
[No Abstract] [Full Text] [Related]
13. The war on cancer: progress at what price?
Konski A
J Clin Oncol; 2011 Apr; 29(12):1503-4. PubMed ID: 21402613
[No Abstract] [Full Text] [Related]
14. Palliative care programs still face obstacles in mainstream cancer care.
Benowitz S
J Natl Cancer Inst; 2013 Mar; 105(6):372-4. PubMed ID: 23457209
[No Abstract] [Full Text] [Related]
15. [Health related quality of life and endpoints in oncology].
Bonnetain F
Cancer Radiother; 2010 Oct; 14(6-7):515-8. PubMed ID: 20674446
[TBL] [Abstract][Full Text] [Related]
16. The cost of treating cancer patients: treatments versus reimbursements.
Goldstein MG
Md Med; 2011; 12(4):15. PubMed ID: 22455202
[No Abstract] [Full Text] [Related]
17. [The economic burden of cancer and the access to innovation should boost the use of real world data].
Thierry JP
Bull Cancer; 2017 Jun; 104(6):495-496. PubMed ID: 28578773
[No Abstract] [Full Text] [Related]
18. Performance metrics in oncology.
Barr TR
Am J Manag Care; 2013; 19 Spec No. 3():E7. PubMed ID: 23725328
[No Abstract] [Full Text] [Related]
19. [Thinking of oncology. Oncologic aspects in the report of the Hungarian Court of Auditors I].
Telekes A
Orv Hetil; 2008 Feb; 149(8):369-71. PubMed ID: 18281235
[No Abstract] [Full Text] [Related]
20. Affordable oncologic care: a challenging goal.
Barton MK
CA Cancer J Clin; 2014; 64(2):75-8. PubMed ID: 24420975
[No Abstract] [Full Text] [Related]
[Next] [New Search]
